Compounded tirzepatide is a prescription medication prepared by a compounding pharmacy or outsourcing facility rather than manufactured as an FDA-approved product. It is intended to contain tirzepatide, the active ingredient in the FDA-approved medications Mounjaro and Zepbound. However, compounded tirzepatide is not FDA-approved and has not gone through FDA review for safety, effectiveness, or quality before marketing.
As of May 31, 2026, FDA had received more than 730 adverse-event reports associated with compounded tirzepatide. FDA notes that these reports do not always prove the product caused the event, and adverse events may be underreported.
Compounded Tirzepatide at a Glance
| Question | Answer |
|---|---|
| What is it? | A customized or altered preparation containing, or claiming to contain, tirzepatide |
| Is it FDA-approved? | No |
| Is it the same as Mounjaro or Zepbound? | No. It may contain tirzepatide, but its formulation, concentration, packaging, and quality controls can differ |
| How is it usually supplied? | Often as a multidose vial that requires a syringe, although products vary |
| Why do people seek it? | Access, cost, supply issues, or a specific medical need |
| Main concerns | Dosing errors, contamination, incorrect concentration, improper storage, and uncertain quality |
How Does Tirzepatide Work?
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. These actions can increase glucose-dependent insulin secretion, reduce glucagon levels, decrease food intake, and lower blood glucose and body weight.
FDA-approved tirzepatide products include:
- Mounjaro, approved to improve blood sugar control in adults with type 2 diabetes when used with diet and exercise.
- Zepbound, approved for chronic weight management in certain adults with obesity or overweight and for moderate-to-severe obstructive sleep apnea in adults with obesity.
These approvals apply to the branded products and their FDA-reviewed manufacturing processes. They do not automatically apply to compounded tirzepatide.
How Is Compounded Tirzepatide Different From Mounjaro or Zepbound?
Compounded tirzepatide is not a generic version of Mounjaro or Zepbound. FDA-approved generic drugs must meet specific requirements for quality and therapeutic equivalence. Compounded drugs do not go through that approval process.
| Feature | Compounded tirzepatide | Mounjaro or Zepbound |
|---|---|---|
| FDA approval | Not FDA-approved | FDA-approved |
| Pre-market FDA review | No FDA review of the finished compounded product before marketing | Yes |
| Formulation | May vary by compounder | Standardized manufacturer formulation |
| Concentration | Can vary between pharmacies or prescriptions | Defined product strengths |
| Delivery system | Commonly a vial and syringe | FDA-approved pens, vials, or other labeled presentations |
| Evidence | Not supported by the same product-specific FDA approval process | Reviewed clinical and manufacturing data |
| Labeling | Pharmacy-specific instructions | FDA-approved prescribing information |
A compounded product may contain the same active molecule as an FDA-approved product. That does not establish that it has the same strength, sterility, stability, delivery system, or clinical performance as Mounjaro or Zepbound. FDA has warned companies against marketing compounded products as the same as FDA-approved drugs or as generic equivalents.
Why Is Tirzepatide Compounded?
Compounding may be appropriate when a patient has a medical need that an FDA-approved medication cannot meet. Examples include an allergy to an inactive ingredient or a need for a dosage form that is not commercially available. FDA says compounded drugs should generally be reserved for situations in which an FDA-approved product cannot meet the patient's needs or is not commercially available.
Some people encounter compounded tirzepatide through telehealth companies that market it as a lower-cost or more accessible option. That marketing does not prove the product is FDA-approved, equivalent to Mounjaro or Zepbound, or appropriate for a particular patient.
What Are the Risks of Compounded Tirzepatide?
Compounded tirzepatide carries the known risks of tirzepatide, along with added risks related to preparation, labeling, storage, and administration.
- Dosing errors: Concentrations may differ between pharmacies, and instructions may use milligrams, milliliters, or syringe "units." Confusing these measurements can result in too much or too little medication.
- Incorrect titration: FDA has received reports involving compounded tirzepatide doses that exceeded the approved label's dose, frequency, or rate of dose increases.
- Contamination: Sterile injectable products can become contaminated if they are prepared or handled improperly.
- Incorrect strength: A product may contain more or less active ingredient than the label states.
- Storage problems: Injectable GLP-1 medicines may lose quality if they are shipped or stored outside the required temperature range.
- Counterfeit or fraudulent products: FDA has identified compounded products with false pharmacy information or labels that did not accurately identify the compounder.
The labeling for FDA-approved tirzepatide products also includes warnings about thyroid C-cell tumors observed in rats, gastrointestinal reactions, pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycemia when combined with certain diabetes medicines, and allergic reactions. Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Is Compounded Tirzepatide Legal?
The legal status depends on the compounder, prescription, formulation, and applicable federal and state requirements.
In an April 1, 2026 update, FDA stated that tirzepatide was not on the FDA drug shortage list and did not appear on the federal 503B bulk drug substances list at that time. On April 30, 2026, FDA announced that it was proposing to exclude tirzepatide from the 503B bulk list after finding no demonstrated clinical need for outsourcing facilities to compound it from bulk substance.
This does not mean every compounded tirzepatide product has the same legal status. A licensed healthcare professional and pharmacy must assess whether a specific prescription and compounding process meet applicable requirements.
How Can Patients Reduce the Risk?
Patients can reduce the risk by checking the prescriber, pharmacy, concentration, storage, and administration instructions before using compounded tirzepatide.
- Obtain a prescription from a licensed healthcare professional.
- Identify the actual compounding pharmacy, not only the telehealth company selling the treatment.
- Confirm the concentration in milligrams per milliliter and obtain written instructions for measuring the dose.
- Ask which syringe size to use and how the prescribed milligram dose converts to the syringe markings.
- Do not use a product labeled "research use only" or "not for human consumption."
- Do not use an injectable product that arrives warm or without adequate refrigeration. FDA says storage problems can affect product quality.
- Use a new sterile needle and syringe for every dose.
- Follow the vial discard instructions carefully. FDA advises discarding a multidose vial within 28 days after first use, even if medication remains, because contamination risk increases over time.
Bottom Line
Compounded tirzepatide is a non-FDA-approved preparation containing or claiming to contain tirzepatide. It is not the same as Mounjaro or Zepbound, is not a generic equivalent, and does not receive the same FDA pre-market review for safety, effectiveness, and quality.
When an FDA-approved tirzepatide product is medically appropriate and available, it generally offers more predictable formulation, dosing, labeling, and quality oversight. Compounded tirzepatide should be used only through a licensed prescriber and a properly identified, state-licensed pharmacy when an FDA-approved option cannot meet the patient's needs.